Research programme: anti-CD72 human monoclonal antibodies - CrucellAlternative Names: Anti-CD72 human monoclonal antibodies research programme - Crucell
Latest Information Update: 26 Jan 2005
At a glance
- Originator Crucell
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Leukaemia
Most Recent Events
- 26 Jan 2005 Discontinued - Preclinical for Leukaemia in Netherlands (unspecified route)
- 11 Feb 2002 New profile
- 11 Feb 2002 Preclinical development for Leukaemia in Netherlands (Unknown route)